Phase I Study of BCMA CAR-T using instant manufacturing platform or traditional production process for relapsed/refractory multiple myeloma therapy

被引：0

作者：

Liu, Hui ^{[1
]}

Wang, Ting ^{[1
]}

Yang, Yazi ^{[1
]}

Feng, Ru ^{[1
]}

Li, Jiangtao ^{[1
]}

Zhang, Chunli ^{[1
]}

Bai, Jiefei ^{[1
]}

Ding, Yanping ^{[2
]}

Liu, Guanghua ^{[2
]}

Wu, Fei ^{[2
]}

Lu, Xinan ^{[2
]}

He, Ting ^{[2
]}

机构：

[1] Beijing Hosp, Beijing, Peoples R China

[2] Beijing Imunopharm Technol Co Ltd, Beijing, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-07

引用

页码：S5 / S5

页数：1

共 50 条

[1] CAR-T Therapy in Relapsed Refractory Multiple Myeloma
Ding, Hong
Wu, Yu
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (27) : 4362 - 4382
[2] Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <3 Days Using the High-Performance Platform
Liu, Hui
Wang, Ting
Yang, Yazi
Feng, Ru
Li, Jiangtao
Zhang, Chunli
Bai, Jiefei
Ding, Yanping
Liu, Guanghua
Wu, Fei
Lu, Xinan
Li, Jian
He, Ting
BLOOD, 2022, 140 : 10307 - 10308
[3] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
Feng, Deming
Sun, Jian
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
[4] BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
Yuhan Yan
Yixuan Tu
Qian Cheng
Jian Zhang
Erhua Wang
Zuqun Deng
Yan Yu
Liwen Wang
Rui Liu
Ling Chu
Liqing Kang
Jing Liu
Xin Li
Journal of Translational Medicine, 22 (1)
[5] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
Zhang, Xiaohui
Ouyang, Chenxi
Sun, Guofeng
Liu, Hongfeng
Qi, Junyuan
Suo, Xiaohui
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
[6] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
Yao, Xin
Zhu, Shigui
Huang, Jiaqi
Qu, Xiaoyan
Zhu, Judy
Wei, Yutian
Lan, Liping
Lv, Xiaoteng
Wu, Junfeng
Wang, Rirfei
Yang, Dingzhu
Zheng, Chengxiao
Zhao, DiJun
Fan, Lei
Huang, Fei
Lu, Hua
Zhang, Chaocan
Chen, Cheng
Li, Yanfeng
Ren, Jiaqiang
Zhang, Li
Humphries, Michael
Li, Jianyong
Yao, Yihong
BLOOD, 2019, 134
[7] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
Zhang, Hua
Gao, Lei
Liu, Li
Wang, Jishi
Wang, Sanbin
Gao, Li
Zhang, Cheng
Liu, Yao
Kong, Peiyan
Liu, Jia
He, Jiaping
Han, Yu
Shi, Hua
He, Yan
Ye, Xun
Zhao, Yi
Cao, Wei
Shen, Lianjun
Zhang, Xi
BLOOD, 2019, 134
[8] BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
Wang, Yiyun
Zu, Cheng
Teng, Xinyi
Yang, Li
Zhang, Mingming
Hong, Ruimin
Zhao, Houli
Cui, Jiazhen
Xu, Huijun
Hongsheng, Alex Chang
Hu, Yongxian
Huang, He
JOURNAL OF IMMUNOTHERAPY, 2022, 45 (01) : 25 - 34
[9] Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Samer Al Hadidi
Aniko Szabo
Jean Esselmann
Lindsay Hammons
Munawwar Hussain
Yetunde Ogunsesan
Nishanth Thalambedu
Fatima Khan
Jaskirat Sethi
Abhishek Janardan
Sabarinath Venniyil Radhakrishnan
Sharmilan Thanendrarajan
Carolina Schinke
Binod Dhakal
Siegfried Janz
Saurabh Chhabra
Anita D’Souza
Maurizio Zangari
Frits van Rhee
Meera Mohan
Bone Marrow Transplantation, 2023, 58 : 443 - 445
[10] Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Al Hadidi, Samer
Szabo, Aniko
Esselmann, Jean
Hammons, Lindsay
Hussain, Munawwar
Ogunsesan, Yetunde
Thalambedu, Nishanth
Khan, Fatima
Sethi, Jaskirat
Janardan, Abhishek
Radhakrishnan, Sabarinath Venniyil
Thanendrarajan, Sharmilan
Schinke, Carolina
Dhakal, Binod
Janz, Siegfried
Chhabra, Saurabh
D'Souza, Anita
Zangari, Maurizio
van Rhee, Frits
Mohan, Meera
BONE MARROW TRANSPLANTATION, 2023, 58 (04) : 443 - 445

← 1 2 3 4 5 →